Aaron Berger, MD, discusses how different formulations of abiraterone acetate can be selected based on patient compliance factors, particularly regarding fasting requirements, for treating both metastatic castration-resistant prostate cancer and high-risk localized prostate cancer cases.
EP. 1: A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
June 16th 2025A panelist discusses how a man aged 74 years with mCRPC who progressed on enzalutamide was successfully treated with abiraterone, highlighting the importance of selecting the appropriate formulation based on patient adherence and lifestyle factors.
EP. 2: Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
June 16th 2025A panelist discusses how adherence considerations are crucial when selecting between different abiraterone formulations, emphasizing that the microformulation offers flexibility by allowing administration with or without food compared with the traditional fasting requirements.
EP. 3: Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability
June 23rd 2025A panelist discusses how food significantly affects abiraterone absorption, particularly fatty meals, which can increase absorption to dangerous levels, making the microformulation advantageous by eliminating fasting concerns.
EP. 4: The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
June 23rd 2025A panelist discusses how patient comorbidities like diabetes and liver disease influence abiraterone formulation selection, noting that some physicians worry about steroid effects on blood glucose and the importance of monitoring liver function.
EP. 5: A 62-Year-Old Man With High-Risk Localized Prostate Cancer
June 30th 2025A panelist discusses how a 62-year-old man with high-risk localized prostate cancer was treated with intensified therapy, including abiraterone plus radiation, but experienced tolerability issues with the traditional fasting formulation.
EP. 6: The Role of Genomic Classifiers in Guiding Therapy for Localized High-Risk Prostate Cancer
June 30th 2025A panelist discusses how genomic classifiers play a crucial role in determining whether treatment intensification with agents like abiraterone is beneficial for patients with high-risk localized prostate cancer.
EP. 7: Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
July 7th 2025A panelist discusses how, for high-risk localized prostate cancer with questionable lymph node involvement, radiation therapy combined with systemic treatment may be preferable to radical prostatectomy due to the ability to treat a wider field of potential microscopic disease.
EP. 8: Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
July 7th 2025A panelist discusses how patients having difficulty with traditional abiraterone fasting requirements can be switched to microsized abiraterone (taken with food) or off-label low-dose abiraterone with low-fat breakfast, though adherence to dietary restrictions remains challenging.
EP. 11: Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
July 21st 2025A panelist discusses how patients with high-risk localized prostate cancer receiving treatment intensification should complete an 18- to 24-month course of systemic therapy with radiation for optimal cure rates, rather than stopping early due to prostate-specific antigen (PSA) response alone.